-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Faeth Therapeutics, Raises Price Target to $60

Benzinga·11/10/2026 19:19:03
Diffusion vocale
Citigroup analyst Geoff Meacham maintains Faeth Therapeutics (NASDAQ:FTH) with a Buy and raises the price target from $55 to $60.